INMUNE BIO INC. Operating Lease, Right-of-Use Asset, Amortization Expense
INMUNE BIO INC. (INMB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $89.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2023-11-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-11-01
- 2022-09-30: Operating Lease, Right-of-Use Asset, Amortization Expense 9 month $89.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|
| 2022-09-30 | $89.00K 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |